8-K current report · filed Nov 12, 2026

Fulcrum Therapeutics, Inc. (FULC) 8-K Current Report: November 12, 2026

Item 8.01FULC overview

Short answer

Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 8.01 (Other Events). Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash.

Fulcrum Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash
  • Closing depends on the proposed Fulcrum-Slate merger, or necessary approvals if the merger terminates
  • Sale proceeds expected in escrow before merger closing and credited to Fulcrum’s net cash
  • Higher net cash expected to increase the cash dividend payable to Fulcrum stockholders
  • Transaction adds merger-closing risk because asset-sale proceeds and resulting dividend depend on required conditions being satisfied

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Fulcrum Therapeutics, Inc. 8-K filings

Get the next FULC 8-K as it lands

Follow FULC for push alerts, or ask the research agent what this filing means.